目的 觀察復方苦參注射液聯(lián)合XELOX化療方案治療術(shù)后結(jié)直腸癌患者的臨床療效。方法 選擇2021年1月—2022年6月在長春市人民醫(yī)院手術(shù)的80例結(jié)直腸癌患者，按照治療方法分為對照組（40例）和治療組（40例）。對照組采用XELOX化療方案治療，第1天將130 mg/m²注射用奧沙利鉑混在250 mL葡萄糖注射液中靜脈滴注2～6 h，同時口服卡培他濱片，2次/d，每次1 000 mg/m²。治療組在對照組基礎(chǔ)上，從第1天開始將20 mL復方苦參注射液加入250 mL生理鹽水中靜脈注射，1次/d，連續(xù)治療14 d，間隔7 d。兩組均以21 d為1個療程，持續(xù)治療2個療程。觀察兩組患者臨床療效，比較治療前后兩組T淋巴細胞和NK細胞水平，血紅蛋白（Hb）、白蛋白（Alb）和轉(zhuǎn)鐵蛋白（TRF）指標水平及不良反應情況。結(jié)果 治療后，治療組總有效率為87.50%，明顯高于對照組患者（60.00%，P＜0.05）。治療后，兩組CD3^＋、CD4^＋、CD4^＋/CD8^＋水平和NK細胞水平均高于治療前，而CD8^＋水平低于治療前，且治療組T淋巴細胞和NK細胞水平均明顯好于對照組（P＜0.05）。治療后，兩組患者Hb、Alb、TRF高于治療前（P＜0.05），且治療組明顯高于對照組（P＜0.05）。治療后，治療組出現(xiàn)胃腸道反應、肝功能異常、神經(jīng)毒性和骨髓抑制等并發(fā)癥的患者數(shù)均低于對照組（P＜0.05）。結(jié)論 復方苦參注射液聯(lián)合XELOX化療方案對術(shù)后結(jié)直腸癌患者具有較好的療效，可提高患者免疫功能及營養(yǎng)狀況，且安全性高。

Objective To observe the clinical effect of compound matrine injection combined with XELOX chemotherapy in treatment of colorectal cancer. Methods Patients (80 cases) with colorectal cancer in Changchun People’s Hospital from January 2021 to June 2022 were divided into control (40 cases) and treatment (40 cases) group according to the treatment. Patients in the control group were administered with XELOX chemotherapy regimen, 130 mg/m² Oxaliplatin for injection was mixed with 250 mL glucose injection for the 1st day, and they were intravenous dripped for 2 — 6 h, and Capecitabine Tablets were taken orally, twice daily, 1 000 mg/m² each time. Patients in the treatment group were iv administered with Compound Kushen Injection on the basis of the control group for 14 d, then stopped for 7 d, 20 mL added into normal saline 250 mL. 21 days as a course of treatment, and patients in two groups were treated for 2 courses. After treatment, the clinical evaluation was evaluated, and the T-lymphocyte and NK cell levels，the levels of Hb, Alb and TRF, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of patients in the treatment group was 87.50%, which was significantly higher than that in the control group (60.00%, P < 0.05). After treatment, the levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺ and NK cells in two groups were higher than those before treatment, while the level of CD8⁺ was lower than that before treatment, and the levels of T lymphocytes and NK cells in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the indexes of Hb, Alb and TRF in two groups were higher than those before treatment (P < 0.05), and which in the treatment group were significantly higher than those in control group (P < 0.05). After treatment, the patients with complications such as gastrointestinal reaction, abnormal liver function, neurotoxicity and myelosuppression in the treatment group were less than the control group (P < 0.05). Conclusion Compound Kushen Injection combined with XELOX chemotherapy regimen has a good effect on postoperative colorectal cancer patients, which can improve the immune function and nutritional status of patients, and high safety.

R979.1